NYSE$AORT
Artivion Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Reported an 8% increase in revenue on a GAAP basis and a 10% increase on a non-GAAP constant currency basis, driven by On-X and aortic stent graft revenue growth.
Artivion reported strong first quarter results with a constant currency revenue growth of 10% year-over-year. The company is on track to achieve or exceed the revenue and EBITDA growth targets for 2023 and beyond. They also received an Approvable Letter from the FDA for the PerClot PMA and expects approval after the report for their recent pre-approval inspection is finalized.
- Achieved revenue of $83.2 million, an 8% increase on a GAAP basis and a 10% increase on a non-GAAP constant currency basis.
- On-X revenues increased 23% on a GAAP basis and 24% on a non-GAAP constant currency basis.
- Aortic stent graft revenues increased 3% on a GAAP basis and 8% on a non-GAAP constant currency basis.
- Received notice from the FDA that the PerClot PMA is approvable subject to finalization of the Establishment Inspection Report (EIR) for our recent pre-approval inspection
Headline financials
Revenue & EPS history
Artivion · Revenue · Quarterly
$83.2M
Revenue by segment
Artivion · $13.7M total across 1 segment · Q4 2020
- On-X$13.7M+2.4%100.0%
Forward guidance
Artivion is raising its revenue guidance range and now expects constant currency revenue growth of between 9% and 12% for the full year 2023 compared to 2022. The Company expects revenues to be in a range of between $337.0 million and $348.0 million. Additionally, Artivion expects adjusted EBITDA to increase greater than 25% in 2023 compared to 2022, resulting in adjusted EBITDA in excess of $52.0 million in 2023.
Tailwinds
- Expects constant currency revenue growth of between 9% and 12% for the full year 2023 compared to 2022.
- Revenues to be in a range of between $337.0 million and $348.0 million.
- Adjusted EBITDA to increase greater than 25% in 2023 compared to 2022.
- Adjusted EBITDA in excess of $52.0 million in 2023.
- Company is raising its revenue guidance range.
Headwinds
- The benefits anticipated from the Ascyrus Medical LLC transaction and Endospan agreements may not be achieved at all or at the levels we had originally anticipated.
- The benefits anticipated from our clinical trials may not be achieved or achieved on our anticipated timeline.
- Our products may not be able to consistently retain their existing regulatory approvals or special regulatory approvals in order to be commercialized.
- Products in our pipeline may not receive regulatory approval at all or receive regulatory approval on our anticipated timelines.
- Our products that obtain regulatory approval may not be adopted by the market as much as we anticipate or at all.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2023
+1.0%
Avg return
Earnings day
+1.1%
Avg return
5 days after
+3.3%
Avg return
30 days after
52%
33 / 64 earnings
Positive
+23.5%
Q1 2021
Best reaction
-15.7%
Q4 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.8% | -36.8% | -43.2% | |
| Q3 2025 | -5.9% | +0.3% | -6.1% | |
| Q1 2025 | +14.9% | +21.6% | +22.5% | |
| Q4 2024 | -8.2% | -8.8% | -12.0% | |
| Q3 2024 | -2.5% | -5.8% | +0.7% | |
| Q2 2024 | -1.2% | -0.3% | -0.2% | |
| Q1 2024 | +13.6% | +12.4% | +12.0% | |
| Q4 2023 | +7.1% | +6.5% | +12.5% | |
| Q3 2023 | +10.5% | +7.1% | +40.6% | |
| Q2 2023 | -3.3% | -1.7% | +1.9% | |
| Q1 2023 | +12.7% | +9.1% | +13.4% | |
| Q4 2022 | +4.3% | -1.5% | -11.7% | |
| Q3 2022 | -1.9% | -3.2% | +18.7% | |
| Q2 2022 | -1.8% | -1.2% | -3.9% | |
| Q1 2022 | -11.4% | -21.6% | -12.4% | |
| Q4 2021 | -0.1% | -1.7% | +22.4% | |
| Q3 2021 | +4.3% | +2.6% | -16.1% | |
| Q2 2021 | +1.3% | +1.2% | -2.6% | |
| Q1 2021 | +23.5% | +21.1% | +22.0% | |
| Q4 2020 | +0.8% | +1.1% | +1.3% | |
| Q3 2020 | -4.9% | +10.5% | +17.1% | |
| Q2 2020 | +1.6% | +4.7% | +7.3% | |
| Q1 2020 | -4.0% | -2.0% | -1.6% | |
| Q4 2019 | -8.1% | -9.3% | -27.2% | |
| Q3 2019 | -7.7% | -3.4% | +1.7% | |
| Q2 2019 | -4.6% | -6.3% | -11.4% | |
| Q1 2019 | +2.1% | +4.0% | -5.5% | |
| Q4 2018 | -15.2% | -4.6% | +0.1% | |
| Q3 2018 | -4.7% | -1.1% | -3.3% | |
| Q2 2018 | +9.4% | +10.1% | +15.9% | |
| Q1 2018 | +6.2% | +12.3% | +22.9% | |
| Q4 2017 | +12.8% | +9.9% | +0.8% | |
| Q3 2017 | -2.7% | -4.8% | +1.8% | |
| Q2 2017 | +3.1% | -1.3% | -1.6% | |
| Q1 2017 | +13.2% | +12.6% | +12.3% | |
| Q4 2016 | -15.7% | -9.7% | -11.5% | |
| Q3 2016 | -1.5% | +0.0% | +18.2% | |
| Q2 2016 | +14.6% | +21.4% | +28.2% | |
| Q1 2016 | -1.8% | — | — | |
| Q4 2015 | +12.6% | — | — | |
| Q3 2015 | +11.1% | — | — | |
| Q2 2015 | -0.4% | — | — | |
| Q1 2015 | +4.0% | — | — | |
| Q4 2014 | -4.2% | — | — | |
| Q3 2014 | -6.1% | — | — | |
| Q2 2014 | +6.4% | — | — | |
| Q1 2014 | -6.0% | — | — | |
| Q4 2013 | -9.1% | — | — | |
| Q3 2013 | +10.6% | — | — | |
| Q2 2013 | -5.4% | — | — | |
| Q1 2013 | -5.4% | — | — | |
| Q4 2012 | +2.0% | — | — | |
| Q3 2012 | +0.5% | — | — | |
| Q2 2012 | -4.3% | — | — | |
| Q1 2011 | +0.2% | — | — | |
| Q1 2012 | +5.1% | — | — | |
| Q4 2009 | -11.5% | — | — | |
| Q4 2011 | -11.5% | — | — | |
| Q3 2010 | +4.6% | — | — | |
| Q3 2011 | +4.6% | — | — | |
| Q2 2011 | +5.4% | — | — | |
| Q2 2010 | +5.4% | — | — | |
| Q4 2010 | +5.4% | — | — | |
| Q1 2010 | +3.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro